Is AxoGen (AXGN) Outperforming Other Medical Stocks This Year?

Here is how AxoGen (AXGN) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.

Zacks Investment Research • 10 hours ago

AxoGen Q3 Earnings Call Highlights

AxoGen NASDAQ: AXGN reported third-quarter revenue growth of 26.2% as demand for its nerve-repair products increased across its breast, extremities, oral and maxillofacial, and head-and-neck markets. The company also raised its full-year revenue outlook following the October acquisition of BioCircuit and said it plans to begin prostate nerve reconstruction market-development activities in 2027.

MarketBeat • Oct 28, 2026

Axogen, Inc. (AXGN) Q3 2026 Earnings Call Transcript

Axogen, Inc. (AXGN) Q3 2026 Earnings Call Transcript

Seeking Alpha • Oct 28, 2026

Axogen, Inc. Reports Third Quarter 2026 Financial Results

Raises Full Year Revenue Guidance to at Least 29% Growth or $290 million Raises Full Year Revenue Guidance to at Least 29% Growth or $290 million

GlobeNewsWire • Oct 28, 2026

AxoGen (AXGN) Beats Q3 Earnings and Revenue Estimates

AxoGen (AXGN) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.12 per share a year ago.

Zacks Investment Research • Oct 28, 2026

AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth

AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 21, 2026

GMED or AXGN: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or AxoGen (AXGN). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research • Oct 16, 2026

Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026

ALACHUA, Fla. and TAMPA, Fla.

GlobeNewsWire • Oct 14, 2026

Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN)

The heavy selling pressure might have exhausted for AxoGen (AXGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Investment Research • Oct 5, 2026

Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair

ALACHUA, Fla. and TAMPA, Fla.

GlobeNewsWire • Oct 1, 2026